Amanda D Melin, Joseph D Orkin, Mareike C Janiak, Alejandro Valenzuela, Lukas Kuderna, Frank Marrone, Hasinala Ramangason, Julie E Horvath, Christian Roos, Andrew C Kitchener, Chiea Chuen Khor, Weng Khong Lim, Jessica G H Lee, Patrick Tan, Govindhaswamy Umapathy, Muthuswamy Raveendran, R Alan Harris, Ivo Gut, Marta Gut, Esther Lizano, Tilo Nadler, Dietmar Zinner, Minh D Le, Sivakumara Manu, Clément J Rabarivola, Alphonse Zaramody, Nicole Andriaholinirina, Steig E Johnson, Erich D Jarvis, Olivier Fedrigo, Dongdong Wu, Guojie Zhang, Kyle Kai-How Farh, Jeffrey Rogers, Tomas Marques-Bonet, Arcadi Navarro, David Juan, Paramjit S Arora, James P Higham
The novel coronavirus SARS-CoV-2, which in humans leads to the disease COVID-19, has caused global disruption and more than 2 million fatalities since it first emerged in late 2019. As we write, infection rates are at their highest point globally and are rising extremely rapidly in some areas due to more infectious variants. The primary target of SARS-CoV-2 is the cellular receptor angiotensin-converting enzyme-2 (ACE2). Recent sequence analyses of the ACE2 gene predict that many nonhuman primates are also likely to be highly susceptible to infection...
June 2021: American Journal of Primatology